World Journal of Stem Cells,
Journal Year:
2024,
Volume and Issue:
16(12), P. 990 - 1001
Published: Dec. 12, 2024
In
this
editorial,
we
have
taken
an
in-depth
look
at
the
article
published
by
Wan
et
al
.
The
study
showed
that
preconditioning
mesenchymal
stem
cells
(MSCs)
protected
them
against
programmed
cell
death,
and
increased
their
survival
rate
therapeutic
potential.
Autophagy,
a
type
of
is
major
intracellular
degradation
recycling
pathway
crucial
for
maintaining
cellular
homeostasis,
self-renewal,
pluripotency.
We
explored
relationship
between
autophagy
MSCs
to
determine
role
in
applications
MSCs.
International Journal of Nanomedicine,
Journal Year:
2025,
Volume and Issue:
Volume 20, P. 3219 - 3234
Published: March 1, 2025
Osteoarthritis
(OA)
is
characterized
by
the
degeneration
of
articular
cartilage
caused
several
factors
which
novel
most
trends
include
microbiota.
Specific
microbiota
and
role
in
development
OA
less
clear.
The
presumed
to
influence
occurrence
progression
mainly
via
immune
modulation.
In
recent
years,
bone
marrow
mesenchymal
stem
cells
(MSCs)
have
shown
great
potential
for
treatment
OA,
however,
therapeutic
efficiency
has
been
seriously
affected
harsh
microenvironment
joint
cavity.
At
present,
many
strategies
used
enhance
function
MSCs,
among
them,
engineering
are
a
promising
method.
Therefore,
this
review
focuses
on
latest
research
how
affects
cell
repair,
use
engineered
MSCs
OA.
addition,
can
exosomes
as
strategy
treating
Our
provides
comprehensive
perspective
therapy
Frontiers in Cell and Developmental Biology,
Journal Year:
2025,
Volume and Issue:
13
Published: March 27, 2025
Osteoarthritis
(OA)
and
type
2
diabetes
mellitus
(T2DM)
often
coexist
due
to
shared
risk
factors
high
prevalence,
but
effective
treatment
methods
are
currently
lacking.
Mesenchymal
stromal/stem
cell-derived
exosomes
(MSC-Exos)
have
regenerative
properties
that
can
repair
cartilage
damage,
lower
blood
sugar
levels,
improve
pancreatic
β
cell
function,
showing
great
potential
in
tissue
repair.
This
review
primarily
explores
the
application
of
MSC-Exos
OA
T2DM,
mechanisms
MSC-Exos,
therapeutic
strategies
engineered
exosomes.
Although
MSC-Exo
therapy
shows
promising
potential,
further
research
is
needed
validate
its
safety
feasibility.
Orthopaedic Surgery,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 2, 2025
Osteoarthritis
(OA)
is
a
degenerative
disease
characterized
by
cartilage
abrasion
and
pain,
affecting
millions
globally.
However,
current
treatments
focus
on
symptom
management
rather
than
modifying
development.
Recent
studies
have
indicated
that
low-density
lipoprotein
receptor-related
protein
1
(LRP1)
associated
with
maintaining
homeostasis
through
its
involvement
in
endocytosis
signaling
pathways.
LRP1
facilitates
the
removal
of
extracellular
matrix
(ECM)-degrading
enzymes,
including
disintegrin
metalloproteinase
thrombospondin
motifs
(ADAMTSs)
metalloproteinases
(MMPs),
thereby
protecting
against
excessive
breakdown.
OA
shows
increased
shedding
LRP1,
leading
to
reduced
endocytic
capacity
elevated
levels
these
contributing
accelerated
ECM
also
involved
key
pathways,
such
as
Wnt/β-catenin,
transforming
growth
factor-beta
(TGF-β),
nuclear
factor-kappa
B
(NF-κB),
which
regulate
processes
like
chondrocyte
proliferation,
apoptosis,
differentiation,
autophagy.
Dysregulation
combined
impaired
LRP1-mediated
endocytosis,
fosters
catabolic
environment
osteoarthritic
cartilage.
Emerging
therapies
targeting
gene
interventions,
exosome-based
therapies,
small-molecule
modulators,
show
potential
restoring
function,
reducing
degradation,
promoting
joint
repair.
This
review
emphasizes
significance
development
explores
therapeutic
target
for
creating
disease-modifying
strategies
maintain
integrity
enhance
patient
well-being.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: April 10, 2025
Orthopedic
diseases
pose
significant
challenges
to
public
health
due
their
high
prevalence,
debilitating
effects,
and
limited
treatment
options.
Additionally,
orthopedic
tumors,
such
as
osteosarcoma,
chondrosarcoma,
Ewing
sarcoma,
further
complicate
the
landscape.
Current
therapies,
including
pharmacological
treatments
joint
replacement,
address
symptoms
but
fail
promote
true
tissue
regeneration.
Cell-based
which
have
shown
successful
clinical
results
in
cancers
other
diseases,
emerged
a
promising
solution
repair
damaged
tissues
restore
function
tumors.
This
review
discusses
advances
potential
application
of
cell
therapy
for
with
particular
focus
on
osteoarthritis,
bone
fractures,
cartilage
degeneration,
We
explore
mesenchymal
stromal
cells
(MSCs),
chondrocyte
transplantation,
engineered
immune
induced
pluripotent
stem
enhance
regeneration
by
modulating
response
addressing
inflammation.
Ultimately,
integration
cutting-edge
therapy,
modulation,
molecular
targeting
strategies
could
revolutionize
providing
hope
patients
seeking
long-term
solutions
conditions.
Current Issues in Molecular Biology,
Journal Year:
2024,
Volume and Issue:
46(11), P. 13078 - 13104
Published: Nov. 17, 2024
Osteoarthritis
(OA)
is
a
chronic
progressive
degenerative
joint
disease
that
affects
significant
portion
of
the
equine
population
and
humans
worldwide.
Current
treatment
options
for
OA
are
limited
incompletely
curative.
Horses
provide
an
excellent
large-animal
model
studying
human
OA.
Recent
advances
in
field
regenerative
medicine
have
led
to
exploration
extracellular
vesicles
(EVs)-cargoes
microRNA,
proteins,
lipids,
nucleic
acids-to
evaluate
their
diagnostic
value
terms
progression
severity,
as
well
potential
cell-free
therapeutic
approach
EVs
transmit
molecular
signals
influence
various
biological
processes,
including
inflammatory
response,
apoptosis,
proliferation,
cell
communication.
In
present
review,
we
summarize
recent
isolation
identification
EVs,
use
biologically
active
components
biomarkers,
distribution
gap
junction
protein
connexin
43.
Moreover,
highlight
role
mesenchymal
stem
cell-derived
tool
musculoskeletal
disorders.
This
review
aims
comprehensive
overview
current
understanding
pathogenesis,
diagnosis,
strategies
particular,
roles
biomarkers
synovial
fluid,
chondrocytes,
plasma
early
detection
discussed.
Biomedicines,
Journal Year:
2024,
Volume and Issue:
12(11), P. 2469 - 2469
Published: Oct. 28, 2024
In
this
review,
we
seek
to
explore
two
distinct
approaches
the
clinical
management
of
OA:
a
prospective
approach,
addressing
primarily
one’s
genetic
predisposition
OA
and
generating
early
intervention
options,
retrospective
aimed
at
halting
or
reversing
progression
post-symptom
onset.
The
remains
challenging,
largely
due
limited
availability
preventative
treatments
failure
existing
therapies
modify
reverse
underlying
pathophysiology.
approach
involves
identification
markers
associated
with
utilizes
in
vitro
vivo
models
characterize
disease
mechanism.
Further,
focuses
on
identifying
predispositions
unique
molecular
subtypes
develop
individualized
treatment
plans
based
patient
genotypes.
While
current
literature
investigating
strategy
has
been
notable,
faces
substantial
challenges,
such
as
extensive
time
burdens
utilization
testing
that
may
not
be
economically
feasible.
Additionally,
there
is
questionable
justification
for
investigations,
given
OA’s
relatively
low
mortality
rates
burden
when
contrasted
diseases
like
specific
forms
cancer,
which
rely
heavily
approach.
Alternatively,
following
symptom
onset
aims
utilize
novel
therapeutics
slow
inflammatory
cascade
typically
seen
progression.
These
treatments,
Hippo
pathway
inhibitors,
have
shown
initial
promise
alleviating
symptomology
by
modulating
cellular
processes
preserve
articular
cartilage.
comparison
likely
more
cost-effective,
widely
applicable,
does
necessitate
thorough
invasive
screening.
However,
must
still
weighed
against
typical
natural
history
progression,
frequently
results
total
knee
arthroplasty
unacceptable
outcomes
15–20%
patients.
From
comparative
analysis
these
approaches,
review
argues
strategy,
ideally
lower
economic
greater
accessibility,
offers
reasonable
effective
solution
context
management.
Using
similar
other
chronic
diseases,
suggest
an
“Inverted
Pyramid”
model
algorithm,
structured
research
development
regimen
prioritizes
first,
subsequent
refinement
resistance
therapies.
We
argue
reduce
need
while
improving
accessibility.
